Cited by 525Parkinson's Disease Mechanisms and TreatmentsAutophagy in Disease and TherapyNuclear Receptors and Signaling

The DOI matches its Crossref record; 114 of the 115 references it cites were found in a registry or an index.

Mitochondrial dysfunction and mitophagy in Parkinson's: from familial to sporadic disease

Ryan, Brent J., Hoek, Selim, Fon, Edward A., Wade-Martins, Richard·2015·Trends in Biochemical Sciences

DOI 10.1016/j.tibs.2015.02.003

Open this paper in CoChat — free account

Abstract

Parkinson's disease (PD) is a progressive neurodegenerative disorder characterised by the preferential loss of dopaminergic neurons in the substantia nigra. Mitochondrial dysfunction is increasingly appreciated as a key determinant of dopaminergic neuronal susceptibility in PD and is a feature of both familial and sporadic disease, as well as in toxin-induced Parkinsonism. Recently, the mechanisms by which PD-associated mitochondrial proteins phosphatase and tensin homolog deleted on chromosome 10 (PTEN)-induced putative kinase 1 (PINK1) and parkin function and induce neurodegeneration have been identified. In addition, increasing evidence implicates other PD-associated proteins such as α-synuclein (α-syn) and leucine-rich repeat kinase 2 (LRRK2) in mitochondrial dysfunction in genetic cases of PD with the potential for a large functional overlap with sporadic disease. This review highlights how recent advances in understanding familial PD-associated proteins have identified novel mechanisms and therapeutic strategies for addressing mitochondrial dysfunction in PD.

Integrity signals

Registry

Crossref · 10.1016/j.tibs.2015.02.003

Cites

114 of 114 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 retracted

TOM40 Mediates Mitochondrial Dysfunction Induced by α-Synuclein Accumulation in Parkinson’s Disease
Bender, A., Desplats, P., Spencer, B. J., Rockenstein, E. M., Adame, A., Elstner, M., Laub, C., Mueller, S. K., Koob, A. O., Mante, M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062277 · Cited by 151
Retracted
PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1
Geisler, S., Holmström, K. M., Skujat, D., Fiesel, F. C., Rothfuss, O. C., Kahle, P. J., & Springer, W. (2010) · Nature Cell Biology · doi:10.1038/ncb2012 · Cited by 2,835
Pathological α-Synuclein Transmission Initiates Parkinson-like Neurodegeneration in Nontransgenic Mice
Luk, K. C., Kehm, V., Carroll, J., Zhang, B., O’Brien, P., Trojanowski, J. Q., & Lee, V. M.-Y. (2012) · Science · doi:10.1126/science.1227157 · Cited by 2,563
ER Tubules Mark Sites of Mitochondrial Division
Friedman, J. R., Lackner, L. L., West, M., DiBenedetto, J. R., Nunnari, J., & Voeltz, G. K. (2011) · Science · doi:10.1126/science.1207385 · Cited by 2,072
PINK1 stabilized by mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent Parkin for mitophagy
Matsuda, N., Sato, S., Shiba, K., Okatsu, K., Saisho, K., Gautier, C. A., Sou, Y.-S., Saiki, S., Kawajiri, S., Sato, F., et al. (2010) · Journal of Cell Biology · doi:10.1083/jcb.200910140 · Cited by 1,969
Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson’s disease
International Parkinson's Disease Genomics Consortium (IPDGC), Nalls, M. A., Parkinson's Study Group (PSG) Parkinson's Research: The Organized GENetics Initiative (PROGENI), 23andMe, GenePD, NeuroGenetics Research Consortium (NGRC), Hussman Institute of Human Genomics (HIHG), Investigator, T. A. J. D., (CHARGE), C. F. H. A. A. R. I. G. E., North American Brain Expression Consortium (NABEC), et al. (2014) · Nature Genetics · doi:10.1038/ng.3043 · Cited by 1,895
MITOCHONDRIAL COMPLEX I DEFICIENCY IN PARKINSON'S DISEASE
Schapira, A. H. V., Cooper, J. A. D., Dexter, D. T., Jenner, P. G., Clark, J. B., & MARSDEN, C. D. (1989) · The Lancet · doi:10.1016/s0140-6736(89)92366-0 · Cited by 1,757
Autophagosomes form at ER–mitochondria contact sites
Hamasaki, M., Furuta, N., Matsuda, A., Nezu, A., Yamamoto, A., Fujita, N., Oomori, H., Noda, T., Haraguchi, T., Hiraoka, Y., et al. (2013) · Nature · doi:10.1038/nature11910 · Cited by 1,683
Ubiquitin is phosphorylated by PINK1 to activate parkin
Koyano, F., Okatsu, K., Kosako, H., Tamura, Y., Go, E., Kimura, M., Kimura, Y., Tsuchiya, H., Yoshihara, H., Hirokawa, T., et al. (2014) · Nature · doi:10.1038/nature13392 · Cited by 1,477
Self-citation
PINK1-Phosphorylated Mitofusin 2 Is a Parkin Receptor for Culling Damaged Mitochondria
Chen, Y., & Dorn, G. W. (2013) · Science · doi:10.1126/science.1231031 · Cited by 1,323

Flagged first, then by citations

Show all 115 references

1 of the 115 references couldn’t be matched to a known paper.

Sorted by citations

Items 101–200 of 525

VPS35pathogenic mutations confer no dominant toxicity but partial loss of function inDrosophilaand genetically interact withparkin
Malik, B. R., Godena, V. K., & Whitworth, A. J. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv322 · Cited by 90
Mitochondria in Multiple Sclerosis: Molecular Mechanisms of Pathogenesis
Patergnani, S., Fossati, V., Bonora, M., Giorgi, C., Marchi, S., Missiroli, S., Rusielewicz, T., Wieckowski, M. R., & Pinton, P. (2016) · International review of cytology · doi:10.1016/bs.ircmb.2016.08.003 · Cited by 86
Alpha-Synuclein Post-translational Modifications: Implications for Pathogenesis of Lewy Body Disorders
Manzanza, N. D. O., Sedlackova, L., & Kalaria, R. N. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.690293 · Cited by 98
LRRK2, GBA and their interaction in the regulation of autophagy: implications on therapeutics in Parkinson's disease
Pang, S. Y.-Y., Lo, R., Ho, P. W., Liu, H., Chang, E. E. S., Leung, C.-T., Malki, Y., Choi, Z. Y.-K., Wong, W. Y., Kung, M. H.-W., et al. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-022-00281-6 · Cited by 86
Regulation of autophagy by mitochondrial phospholipids in health and diseases
Hsu, P., & Shi, Y. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2016.08.003 · Cited by 86
Progression of pathology in PINK1-deficient mouse brain from splicing via ubiquitination, ER stress, and mitophagy changes to neuroinflammation
Torres-Odio, S., Key, J., Hoepken, H.-H., Canet-Pons, J., Valek, L., Roller, B., Walter, M. J., Morales-Gordo, B., Meierhofer, D., Harter, P. N., et al. (2017) · Journal of Neuroinflammation · doi:10.1186/s12974-017-0928-0 · Cited by 86
Mitochondrial Dysfunction in Neurodegenerative Diseases
Yang, H. (2025) · Cells · doi:10.3390/cells14040276 · Cited by 95
Mitochondrial lipids in neurodegeneration
Aufschnaiter, A., Kohler, V., Diessl, J., Peselj, C., Carmona‐Gutiérrez, D., Keller, W., & Büttner, S. (2016) · Cell and Tissue Research · doi:10.1007/s00441-016-2463-1 · Cited by 91
Quantitative proteomic analysis of Parkin substrates in Drosophila neurons
Martinez, A., Lectez, B. L. P., Ramírez, J., Popp, O., Sutherland, J. D., Urbé, S., Dittmar, G., Clague, M. J., & Mayor, U. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0170-3 · Cited by 86
Mitophagy in Parkinson’s Disease: Pathogenic and Therapeutic Implications
Gao, F., Yang, J. Y., Wang, D., Li, C., Fu, Y., Wang, H., He, W., & Zhang, J. (2017) · Frontiers in Neurology · doi:10.3389/fneur.2017.00527 · Cited by 84
Role of Optineurin in the Mitochondrial Dysfunction: Potential Implications in Neurodegenerative Diseases and Cancer
Weil, R., Laplantine, E., Curic, S., & Génin, P. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01243 · Cited by 83
Ferroptosis and Iron Homeostasis: Molecular Mechanisms and Neurodegenerative Disease Implications
Abdukarimov, N., Kokabi, K., & Kunz, J. (2025) · Antioxidants · doi:10.3390/antiox14050527 · Cited by 93
Mitochondria-Associated Membranes (MAMs): Overview and Its Role in Parkinson’s Disease
Rodríguez‐Arribas, M., Yakhine-Diop, S. M. S., Pedro, J. M. B., Gómez‐Suaga, P., Gómez‐Sánchez, R., Martínez-Chacón, G., Fuentes, J. M., González‐Polo, R. A., & Niso‐Santano, M. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-0140-8 · Cited by 82
Decreased sirtuin deacetylase activity in LRRK2 G2019S iPSC-derived dopaminergic neurons
Schwab, A. J., Sison, S. L., Meade, M. R., Broniowska, K. A., Corbett, J. A., & Ebert, A. D. (2017) · Stem Cell Reports · doi:10.1016/j.stemcr.2017.10.010 · Cited by 80
Healthy Human Fecal Microbiota Transplantation into Mice Attenuates MPTP-Induced Neurotoxicity via AMPK/SOD2 Pathway
Xie, Z., Zhang, M., Luo, Y., Jin, D., Guo, X., Yang, W., Zheng, J., Zhang, H., Zhang, L., Deng, C., et al. (2023) · Aging and disease · doi:10.14336/ad.2023.0309 · Cited by 80
“Thus, mitochondrial malfunction is increasingly considered a key determinant of dopaminergic neurodegeneration, serving as an overlapping risk factor for both sporadic and familial cases [11].”
The Contribution of α -Synuclein Spreading to Parkinson’s Disease Synaptopathy
Longhena, F., Faustini, G., Missale, C., Pizzi, M., Spano, P., & Bellucci, A. (2017) · Neural Plasticity · doi:10.1155/2017/5012129 · Cited by 82
Mitochondrial Complex 1, Sigma 1, and Synaptic Vesicle 2A in Early Drug‐Naive Parkinson's Disease
Wilson, H., Pagano, G., de Natale, E. R., Mansur, A., Caminiti, S. P., Polychronis, S., Middleton, L. T., Price, G., Schmidt, K. F., Gunn, R. N., et al. (2020) · Movement Disorders · doi:10.1002/mds.28064 · Cited by 82
Αlpha-Synuclein as a Mediator in the Interplay between Aging and Parkinson’s Disease
Bobela, W., Aebischer, P., & Schneider, B. L. (2015) · Biomolecules · doi:10.3390/biom5042675 · Cited by 75
Prospects of Neurotrophic Factors for Parkinson's Disease: Comparison of Protein and Gene Therapy
Domanskyi, A., Saarma, M., & Airavaara, M. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.065 · Cited by 76
Parkinson's disease and mitophagy: an emerging role for LRRK2
Singh, F., & Ganley, I. G. (2021) · Biochemical Society Transactions · doi:10.1042/bst20190236 · Cited by 79
Understanding the Multiple Role of Mitochondria in Parkinson’s Disease and Related Disorders: Lesson From Genetics and Protein–Interaction Network
Nicoletti, V., Palermo, G., Prete, E. D., Mancuso, M., & Ceravolo, R. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.636506 · Cited by 75
Alpha-synuclein prevents the formation of spherical mitochondria and apoptosis under oxidative stress
Menges, S., Minakaki, G., Schaefer, P. M., Meixner, H., Prots, I., Schlötzer-Schrehardt, U., Friedland, K., Winner, B., Outeiro, T., Winklhofer, K., et al. (2017) · Scientific Reports · doi:10.1038/srep42942 · Cited by 74
Transcriptional activation of antioxidant gene expression by Nrf2 protects against mitochondrial dysfunction and neuronal death associated with acute and chronic neurodegeneration
Goodfellow, M. J., Borcar, A., Proctor, J. L., Greco, T., Rosenthal, R. E., & Fiskum, G. M. (2020) · Experimental Neurology · doi:10.1016/j.expneurol.2020.113247 · Cited by 77
Microglial cGAS drives neuroinflammation in the MPTP mouse models of Parkinson's disease
Ma, C., Liu, Y., Li, S., Ma, C., Huang, J., Wen, S., Yang, S., & Wang, B. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14157 · Cited by 76
Intercellular transfer of pathogenic α-synuclein by extracellular vesicles is induced by the lipid peroxidation product 4-hydroxynonenal
Zhang, S., Eitan, E., Wu, T.-Y., & Mattson, M. P. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.09.016 · Cited by 76
Mitochondrial function and autophagy: integrating proteotoxic, redox, and metabolic stress in Parkinson's disease
Zhang, J., Culp, M. L., Craver, J., & Darley-Usmar, V. M. (2018) · Journal of Neurochemistry · doi:10.1111/jnc.14308 · Cited by 74
The current status of pharmacotherapy for the treatment of Parkinson’s disease: transition from single-target to multitarget therapy
Cheong, S. L., Federico, S., Spalluto, G., Klotz, K., & Pastorin, G. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.05.003 · Cited by 76
The use of fibroblasts as a valuable strategy for studying mitochondrial impairment in neurological disorders
Olesen, M. A., Villavicencio-Tejo, F., & Quintanilla, R. A. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-022-00308-y · Cited by 80
Mitochondrial impairments contribute to Spinocerebellar ataxia type 1 progression and can be ameliorated by the mitochondria-targeted antioxidant MitoQ
Stucki, D., Ruegsegger, C., Steiner, S., Radecke, J., Murphy, M. P., Zuber, B., & Saxena, S. (2016) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2016.07.005 · Cited by 73
Rhomboid proteases in human disease: Mechanisms and future prospects
Düsterhöft, S., Künzel, U., & Freeman, M. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2017.04.016 · Cited by 68
α-Synuclein-Dependent Calcium Entry Underlies Differential Sensitivity of Cultured SN and VTA Dopaminergic Neurons to a Parkinsonian Neurotoxin
Lieberman, O. J., Choi, S. J., Kanter, E., Saverchenko, A., Frier, M. D., Fiore, G. M., Wu, M., Kondapalli, J., Zampese, E., Surmeier, D. J., et al. (2017) · eNeuro · doi:10.1523/eneuro.0167-17.2017 · Cited by 72
Genotype-Phenotype Correlations in Monogenic Parkinson Disease: A Review on Clinical and Molecular Findings
Guadagnolo, D., Piane, M., Torrisi, M. R., Pizzuti, A., & Petrucci, S. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.648588 · Cited by 72
Therapeutic Potential of a Prolyl Hydroxylase Inhibitor FG-4592 for Parkinson’s Diseases in Vitro and in Vivo: Regulation of Redox Biology and Mitochondrial Function
Li, X., Cui, X., Chen, Y., Wu, T., Xu, H., Yin, H., & Wu, Y. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00121 · Cited by 68
Emerging concepts of mitochondrial dysfunction in Parkinson’s disease progression: Pathogenic and therapeutic implications
Rani, L., & Mondal, A. C. (2019) · Mitochondrion · doi:10.1016/j.mito.2019.09.010 · Cited by 68
A30P mutant α-synuclein impairs autophagic flux by inactivating JNK signaling to enhance ZKSCAN3 activity in midbrain dopaminergic neurons
Lei, Z., Cao, G., & Wei, G. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1364-0 · Cited by 72
Mitophagy, a Form of Selective Autophagy, Plays an Essential Role in Mitochondrial Dynamics of Parkinson’s Disease
Wang, X., Feng, S., Wang, Y., Yuan, Y., Li, Z., Chen, N., Wang, Z., & Zhang, Y. (2021) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-021-01039-w · Cited by 66
Degeneration of Dopaminergic Neurons Due to Metabolic Alterations and Parkinson’s Disease
Song, J., & Kim, J. (2016) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2016.00065 · Cited by 69
A single cell high content assay detects mitochondrial dysfunction in iPSC-derived neurons with mutations in SNCA
Little, D., Luft, C., Mosaku, O., Lorvellec, M., Yao, Z., Paillusson, S., Kriston-Vizi, J., Gandhi, S., Abramov, A. Y., Ketteler, R., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-27058-0 · Cited by 68
Drosophila Models of Sporadic Parkinson’s Disease
Nagoshi, E. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113343 · Cited by 69
l -DOPA-induced dyskinesia in Parkinson's disease: Are neuroinflammation and astrocytes key elements?
Bel, E. A. D., Bortolanza, M., Pereira, M. D. S., Bariotto‐dos‐Santos, K., & Raisman‐Vozari, R. (2016) · Synapse · doi:10.1002/syn.21941 · Cited by 67
AKT signalling selectively regulates PINK1 mitophagy in SHSY5Y cells and human iPSC-derived neurons
Soutar, M. P. M., Kempthorne, L., Miyakawa, S., Annuario, E., Melandri, D., Harley, J., O’Sullivan, G. A., Wray, S., Hancock, D. C., Cookson, M. R., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-26949-6 · Cited by 65
Clinical, mechanistic, biomarker, and therapeutic advances in GBA1-associated Parkinson’s disease
Zhang, X., Wu, H., Tang, B., & Guo, J. (2024) · Translational Neurodegeneration · doi:10.1186/s40035-024-00437-6 · Cited by 66
Mitochondria and α-Synuclein: Friends or Foes in the Pathogenesis of Parkinson’s Disease?
Faustini, G., Bono, F., Valerio, A., Pizzi, M., Spano, P., & Bellucci, A. (2017) · Genes · doi:10.3390/genes8120377 · Cited by 66
The epigenetic mechanisms involved in mitochondrial dysfunction: Implication for Parkinson’s disease
Chen, Z., Rasheed, M., & Deng, Y. (2021) · Brain Pathology · doi:10.1111/bpa.13012 · Cited by 61
Oxidative Stress and Neurodegeneration: Insights and Therapeutic Strategies for Parkinson’s Disease
Bej, E., Cesare, P., Volpe, A. R., d’Angelo, M., & Castelli, V. (2024) · Neurology International · doi:10.3390/neurolint16030037 · Cited by 74
The Neuroprotection of Low-Dose Morphine in Cellular and Animal Models of Parkinson’s Disease Through Ameliorating Endoplasmic Reticulum (ER) Stress and Activating Autophagy
Wang, B., Su, C., Liu, T.-T., Zhou, Y., Feng, Y. Y., Huang, Y., Liu, X., Wang, Z.-H., Chen, L., Luo, W., et al. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00120 · Cited by 62
Parkinson’s disease–associated VPS35 mutant reduces mitochondrial membrane potential and impairs PINK1/Parkin-mediated mitophagy
Yu, K., Fokkens, M. R., Reggiori, F., Mari, M. C., & Verbeek, D. S. (2021) · Translational Neurodegeneration · doi:10.1186/s40035-021-00243-4 · Cited by 63
Coordination and redox properties of copper interaction with α-synuclein
Valensin, D., Dell’Acqua, S., Kozłowski, H., & Casella, L. (2016) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2016.04.012 · Cited by 61
α-Arbutin Protects Against Parkinson’s Disease-Associated Mitochondrial Dysfunction In Vitro and In Vivo
Ding, Y., Kong, D., Zhou, T., Yang, N., Xin, C., Xu, J., Wang, Q., Zhang, H., Wu, Q., Lü, X., et al. (2019) · NeuroMolecular Medicine · doi:10.1007/s12017-019-08562-6 · Cited by 63
Dopaminergic system and neurons: Role in multiple neurological diseases
Chen, H., Li, J., Huang, Z., Fan, X., Wang, X., Chen, X., Guo, H., Liu, H., Li, S., Yu, S., et al. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.110133 · Cited by 69
Disease‐specific phenotypes in iPSC‐derived neural stem cells with POLG mutations
Liang, K. X., Kristiansen, C. K., Mostafavi, S., Vatne, G. H., Zantingh, G. A., Kianian, A., Tzoulis, C., Høyland, L. E., Ziegler, M., Pérez, R., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.202012146 · Cited by 62
Neuroprotective mechanisms of ε-viniferin in a rotenone-induced cell model of Parkinson's disease: significance of SIRT3-mediated FOXO3 deacetylation
Zhang, S., Ma, Y., & Feng, J. (2020) · Neural Regeneration Research · doi:10.4103/1673-5374.282264 · Cited by 61
The Dawn of Mitophagy: What Do We Know by Now?
Belousov, D. M., Вячеславовна, М. Е., Somasundaram, S. G., Kirkland, C. E., & Aliev, G. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200522202319 · Cited by 60
Neuroprotective Role of GLP-1 Analog for Retinal Ganglion Cells via PINK1/Parkin-Mediated Mitophagy in Diabetic Retinopathy
Zhou, H., Ma, X., Lin, W., Hao, M., Yu, X., Li, H.-X., Xu, C., & Kuang, H. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.589114 · Cited by 62
Exogenous Alpha-Synuclein Evoked Parkin Downregulation Promotes Mitochondrial Dysfunction in Neuronal Cells. Implications for Parkinson’s Disease Pathology
Wilkaniec, A., Lenkiewicz, A. M., Babiec, L., Murawska, E., Jęśko, H. M., Cieślik, M., Culmsee, C., & Adamczyk, A. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.591475 · Cited by 62
Counteracting PINK/Parkin Deficiency in the Activation of Mitophagy: A Potential Therapeutic Intervention for Parkinson's Disease
Nardin, A., Schrepfer, E., & Ziviani, E. (2016) · Current Neuropharmacology · doi:10.2174/1570159x13666151030104414 · Cited by 61
Editor’s Highlight: Base Excision Repair Variants and Pesticide Exposure Increase Parkinson’s Disease Risk
Sanders, L. H., Paul, K. C., Howlett, E. H., Lawal, H. O., Boppana, S., Bronstein, J. M., Ritz, B. R., & Greenamyre, J. T. (2017) · Toxicological Sciences · doi:10.1093/toxsci/kfx086 · Cited by 58
From the Cover: Manganese and Rotenone-Induced Oxidative Stress Signatures Differ in iPSC-Derived Human Dopamine Neurons
Neely, M. D., Davison, C. A., Aschner, M., & Bowman, A. B. (2017) · Toxicological Sciences · doi:10.1093/toxsci/kfx145 · Cited by 59
PARK2 Mutation Causes Metabolic Disturbances and Impaired Survival of Human iPSC-Derived Neurons
Bogetofte, H., Jensen, P., Ryding, M., Schmidt, S. I., Okarmus, J., Ritter, L., Worm, C. S., Hohnholt, M. C., Azevedo, C., Roybon, L., et al. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00297 · Cited by 62
Self-citation
Mitochondrial CHCHD2: Disease-Associated Mutations, Physiological Functions, and Current Animal Models
Kee, T. R., Espinoza, P., Wehinger, J. L., Bukhari, M. Z., Ermekbaeva, A., Sista, A., Kotsiviras, P., Liu, T., Kang, D. E., & Woo, J. A. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.660843 · Cited by 60
Dysregulation of mitochondrial and proteolysosomal genes in Parkinson’s disease myeloid cells
Navarro, E., Udine, E., Lopes, K. D. P., Parks, M., Riboldi, G., Schilder, B. M., Humphrey, J., Snijders, G. J. L., Vialle, R. A., Zhuang, M., et al. (2021) · Nature Aging · doi:10.1038/s43587-021-00110-x · Cited by 57
Coordinated Action of miR-146a and Parkin Gene Regulate Rotenone-induced Neurodegeneration
Jauhari, A., Singh, T., Mishra, S., Shankar, J., & Yadav, S. (2020) · Toxicological Sciences · doi:10.1093/toxsci/kfaa066 · Cited by 56
Progress in the molecular pathogenesis and nucleic acid therapeutics for Parkinson's disease in the precision medicine era
Li, D., Mastaglia, F. L., Fletcher, S., & Wilton, S. D. (2020) · Medicinal Research Reviews · doi:10.1002/med.21718 · Cited by 59
Amyotrophic Lateral Sclerosis (ALS): Stressed by Dysfunctional Mitochondria-Endoplasmic Reticulum Contacts (MERCs)
Chen, J., Bassot, A., Giuliani, F., & Simmen, T. (2021) · Cells · doi:10.3390/cells10071789 · Cited by 58
A systematic review of molecular approaches that link mitochondrial dysfunction and neuroinflammation in Parkinson’s disease
Mani, S., Sevanan, M., Krishnamoorthy, A., & Sekar, S. (2021) · Neurological Sciences · doi:10.1007/s10072-021-05551-1 · Cited by 59
Mitochondrial dysfunction in metabolism and ageing: shared mechanisms and outcomes?
López‐Lluch, G., Hernández‐Camacho, J. D., Fernández‐Ayala, D. J. M., & Navas, P. (2018) · Biogerontology · doi:10.1007/s10522-018-9768-2 · Cited by 60
Nanoscale monitoring of mitochondria and lysosome interactions for drug screening and discovery
Chen, Q., Shao, X., Tian, Z., Chen, Y., Mondal, P., Liu, F., Wang, F., Ling, P., He, W., Zhang, K., et al. (2019) · Nano Research · doi:10.1007/s12274-019-2331-x · Cited by 54
Mitophagy Regulates Neurodegenerative Diseases
Cen, X., Zhang, M., Zhou, M., Ye, L., & Xia, H. (2021) · Cells · doi:10.3390/cells10081876 · Cited by 60
Dissecting the role of Engrailed in adult dopaminergic neurons – Insights into Parkinson disease pathogenesis
Rekaik, H., de Thé, F.-X. B., Prochiantz, A., Fuchs, J., & Joshi, R. L. (2015) · FEBS Letters · doi:10.1016/j.febslet.2015.10.002 · Cited by 54
Mitochondrial Chaperones in the Brain: Safeguarding Brain Health and Metabolism?
Castro, J. P., Wardelmann, K., Grune, T., & Kleinridders, A. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00196 · Cited by 53
Modulation of Autophagy by Calcium Signalosome in Human Disease
Filippi‐Chiela, E. C., Viegas, M. S., Thomé, M. P. M., Buffon, A., Wink, M. R., & Lenz, G. (2016) · Molecular Pharmacology · doi:10.1124/mol.116.105171 · Cited by 52
LRRK2 inhibitors and their potential in the treatment of Parkinson’s disease: current perspectives
Atashrazm, F., & Dzamko, N. L. (2016) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s102191 · Cited by 57
Cytochrome P450 in the central nervous system as a therapeutic target in neurodegenerative diseases
Navarro‐Mabarak, C., Camacho‐Carranza, R., & Espinosa-Aguirre, J. J. (2018) · Drug Metabolism Reviews · doi:10.1080/03602532.2018.1439502 · Cited by 53
Mitochondrial DNA Double-Strand Breaks in Oligodendrocytes Cause Demyelination, Axonal Injury, and CNS Inflammation
Madsen, P. M., Pinto, M., Patel, S. K., McCarthy, S., Gao, H., Taherian, M., Karmally, S., Pereira, C. V., Dvoriantchikova, G., Ivanov, D., et al. (2017) · Journal of Neuroscience · doi:10.1523/jneurosci.1378-17.2017 · Cited by 53
Therapeutic drug repositioning with special emphasis on neurodegenerative diseases: Threats and issues
Kakoti, B. B., Bezbaruah, R., & Ahmed, N. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1007315 · Cited by 57
Neurological disorders associated with DNA strand-break processing enzymes
Jiang, B., Glover, J. N. M., & Weinfeld, M. (2016) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2016.07.009 · Cited by 53
P2X7 Receptor is Involved in Mitochondrial Dysfunction Induced by Extracellular Alpha Synuclein in Neuroblastoma SH-SY5Y Cells
Wilkaniec, A., Cieślik, M., Murawska, E., Babiec, L., Gąssowska-Dobrowolska, M., Pałasz, E., Jęśko, H. M., & Adamczyk, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21113959 · Cited by 51
Loss of PINK1 leads to metabolic deficits in adult neural stem cells and impedes differentiation of newborn neurons in the mouse hippocampus
Agnihotri, S. K., Shen, R., Li, J., Gao, X., & Büeler, H. (2017) · The FASEB Journal · doi:10.1096/fj.201600960rr · Cited by 50
Parkinsonian features in aging GFAP.HMOX1 transgenic mice overexpressing human HO-1 in the astroglial compartment
Song, W., Cressatti, M., Zukor, H., Liberman, A., Galindez, C., & Schipper, H. M. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.06.017 · Cited by 53
The potential therapy with dental tissue-derived mesenchymal stem cells in Parkinson’s disease
Xiao, Z., Lei, T., Liu, Y., Yang, Y., Bi, W., & Du, H. (2021) · Stem Cell Research & Therapy · doi:10.1186/s13287-020-01957-4 · Cited by 49
DJ ‐1 modulates mitochondrial response to oxidative stress: clues from a novel diagnosis of PARK7
Nottia, M. D., Masciullo, M., Verrigni, D., Petrillo, S., Modoni, A., Rizzo, V., Giuda, D. D., Rizza, T., Niceta, M., Torraco, A., et al. (2016) · Clinical Genetics · doi:10.1111/cge.12841 · Cited by 48
Genetic Determinants of Parkinson's Disease: Can They Help to Stratify the Patients Based on the Underlying Molecular Defect?
Redenšek, S., Trošt, M., & Dolžan, V. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00020 · Cited by 48
Alpha-synuclein oligomer-selective antibodies reduce intracellular accumulation and mitochondrial impairment in alpha-synuclein exposed astrocytes
Gustafsson, G., Lindström, V., Rostami, J., Nordström, E. K. L., Lannfelt, L., Bergström, J. J. E., Ingelsson, M., & Erlandsson, A. (2017) · Journal of Neuroinflammation · doi:10.1186/s12974-017-1018-z · Cited by 48
Apios americana Medikus tuber polysaccharide exerts anti-inflammatory effects by activating autophagy
Chu, Q., Zhang, S., Yu, L., Li, Y., Liu, Y., Ye, X., & Zheng, X. (2019) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2019.03.012 · Cited by 48
Morinda citrifolia and Its Active Principle Scopoletin Mitigate Protein Aggregation and Neuronal Apoptosis through Augmenting the DJ-1/Nrf2/ARE Signaling Pathway
Narasimhan, K. K. S., Jayakumar, D., Velusamy, P., Ashokkumar, S., Mohan, T., Ravi, D. B., Saraswathi, U., Sathyamoorthy, Y. K., Rajasekaran, N. S., & Kalaiselvi, P. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/2761041 · Cited by 55
CNTNAP4 deficiency in dopaminergic neurons initiates parkinsonian phenotypes
Zhang, W., Zhou, M., Lu, W., Gong, J., Gao, F., Li, Y., Xu, X., Lin, Y., Zhang, X., Ding, L., et al. (2020) · Theranostics · doi:10.7150/thno.40798 · Cited by 49
Telomeres in neurological disorders
Anitha, A., Thanseem, I., Vasu, M. M., Viswambharan, V., & Poovathinal, S. A. (2019) · Advances in clinical chemistry · doi:10.1016/bs.acc.2019.01.003 · Cited by 49
Update on the association between alpha‐synuclein and tau with mitochondrial dysfunction: Implications for Parkinson's disease
Feng, S., Wang, Z., Yuan, Y., Sun, H., Chen, N., & Zhang, Y. (2020) · European Journal of Neuroscience · doi:10.1111/ejn.14699 · Cited by 47
Targetable Pathways for Alleviating Mitochondrial Dysfunction in Neurodegeneration of Metabolic and Non-Metabolic Diseases
Millichap, L. E., Damiani, E., Tiano, L., & Hargreaves, I. P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111444 · Cited by 48
The unintended mitochondrial uncoupling effects of the FDA-approved anti-helminth drug nitazoxanide mitigates experimental parkinsonism in mice
Amireddy, N., Puttapaka, S. N., Vinnakota, R. L., Ravuri, H. G., Thonda, S., & Kalivendi, S. V. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.791863 · Cited by 46
NBR1 is dispensable for PARK2-mediated mitophagy regardless of the presence or absence of SQSTM1
Shi, J., Fung, G., Deng, H., Zhang, J.-Q., Fiesel, F. C., Springer, W., Li, X. X., & Luo, H. (2015) · Cell Death and Disease · doi:10.1038/cddis.2015.278 · Cited by 49
Mitochondria-mediated damage to dopaminergic neurons in Parkinson's disease (Review)
Liu, X., Wang, Y., Yu, X., Li, D., & Li, G. (2017) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2017.3255 · Cited by 45
All Roads Lead to Rome: Different Molecular Players Converge to Common Toxic Pathways in Neurodegeneration
Argueti-Ostrovsky, S., Alfahel, L., Kahn, J., & Israelson, A. (2021) · Cells · doi:10.3390/cells10092438 · Cited by 46
Antioxidative role of Traditional Chinese Medicine in Parkinson's disease
Muhammad, F., Liu, Y., Zhou, Y., Yang, H., & Li, H. (2021) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2021.114821 · Cited by 47
Enteric neurons from Parkinson’s disease patients display ex vivo aberrations in mitochondrial structure
Baumuratov, A., Antony, P. M. A., Ostaszewski, M., HeFeng, F. Q., Salamanca, L., Antunes, L., Weber, J., Longhino, L., Derkinderen, P., Koopman, W. J. H., et al. (2016) · Scientific Reports · doi:10.1038/srep33117 · Cited by 43
Mitochondrial DNA in CSF distinguishes LRRK2 from idiopathic Parkinson's disease
Podlesniy, P., Vilas, D., Taylor, P., Shaw, L. M. J., Tolosa, E., & Trullás, R. (2016) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.05.019 · Cited by 45
Sigma receptors and neurological disorders
Piechal, A., Jakimiuk, A. A., & Mirowska-Guzel, D. M. (2021) · Pharmacological Reports · doi:10.1007/s43440-021-00310-7 · Cited by 44
Alpha‐synuclein‐associated changes in PINK1‐PRKN‐mediated mitophagy are disease context dependent
Hou, X., Chen, T. H., Koga, S., Bredenberg, J. M., Faroqi, A. H., Delenclos, M., Bu, G., Wszołek, Z. K., Carr, J. A., Ross, O. A., et al. (2023) · Brain Pathology · doi:10.1111/bpa.13175 · Cited by 42
NME4/nucleoside diphosphate kinase D in cardiolipin signaling and mitophagy
Schlattner, U., Tokarska-Schlattner, M., Epand, R. M., Boissan, M., Lacombe, M., & Kagan, V. E. (2017) · Laboratory Investigation · doi:10.1038/labinvest.2017.113 · Cited by 42
PPEF2 Opposes PINK1-Mediated Mitochondrial Quality Control by Dephosphorylating Ubiquitin
Wall, C. E., Rose, C. M., Adrian, M., Zeng, Y. J., Kirkpatrick, D. S., & Bingol, B. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.10.130 · Cited by 42

Authors: Ryan, B. J., Hoek, S., Fon, E. A., & Wade-Martins, R.
Affiliations: University of Oxford (GB)
Montreal Neurological Institute and Hospital (CA)
ORCID: Ryan, Brent J.
Fon, Edward A.
Venue: Trends in Biochemical Sciences
Publisher: Elsevier BV
Published: 2015-04
Volume: 40
Issue: 4
Pages: 200-210
ISSN: 0968-0004 (ISSN-L)
DOI: 10.1016/j.tibs.2015.02.003
OpenAlex: W2021439462
Cited by: 524
References: 115
Citations by year: 2026: 25 · 2025: 30 · 2024: 37 · 2023: 28 · 2022: 45 · 2021: 65 · 2020: 56 · 2019: 50 · 2018: 63 · 2017: 53 · 2016: 52 · 2015: 20
FWCI: 8.25
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Trends in Biochemical Sciences (publishedVersion)
PubMed (publishedVersion)
Funders: Parkinson's UK (J-0901)
Canadian Institutes of Health Research
Topics: Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Autophagy in Disease and Therapy
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
Keywords: Parkinson's disease, mitochondrial dysfunction, mitophagy, PINK1, Parkin, alpha-synuclein, LRRK2, dopaminergic neurons, familial Parkinson's disease, sporadic Parkinson's disease, neurodegeneration, treatment options
MeSH terms: Animals, Humans, Mitochondria, Parkinson Disease, alpha-Synuclein

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Mitochondrial dysfunction and mitophagy in Parkinson's: from familial to sporadic disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks